Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 91 AL 105

From alpha to omega with Abeta: targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease

De Kimpe L, Scheper W.

Curr Med Chem. 2010;17(3):198-212. doi: 10.2174/092986710790149765.

Methylphenidate for apathy and functional status in dementia of the Alzheimer type

Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F.

Am J Geriatr Psychiatry. 2010 Apr;18(4):371-4. doi: 10.1097/JGP.0b013e3181cabcf6.

Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants

Cornelli U.

Neurodegener Dis. 2010;7(1-3):193-202. doi: 10.1159/000295663. Epub 2010 Mar 12.

Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE)

Gauthier S, Juby A, Dalziel W, Réhel B, Schecter R; EXPLORE investigators.

Curr Med Res Opin. 2010 May;26(5):1149-60. doi: 10.1185/03007991003688888.

Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals

Kim SH, Fraser PE, Westaway D, St George-Hyslop PH, Ehrlich ME, Gandy S.

J Neurosci. 2010 Mar 17;30(11):3870-5. doi: 10.1523/JNEUROSCI.4717-09.2010.

Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches

Galimberti D, Scarpini E.

Curr Aging Sci. 2010 Feb;3(1):46-56. doi: 10.2174/1874609811003010046.

Early Alzheimer's trials: new developments

Vellas B, Aisen PS.

J Nutr Health Aging. 2010 Apr;14(4):293. doi: 10.1007/s12603-010-0064-3.

Pre-dementia Alzheimer's trials: overview

Aisen PS.

J Nutr Health Aging. 2010 Apr;14(4):294. doi: 10.1007/s12603-010-0065-2.

Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease

Holscher C.

Recent Pat CNS Drug Discov. 2010 Jun;5(2):109-17. doi: 10.2174/157488910791213130.

Medication in elderly people: its influence on salivary pattern, signs and symptoms of dry mouth

Leal SC, Bittar J, Portugal A, Falcão DP, Faber J, Zanotta P.

Gerodontology. 2010 Jun;27(2):129-33. doi: 10.1111/j.1741-2358.2009.00293.x. Epub 2010 Mar 11.

Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases

Granero AL, Lucchetti G.

Braz J Psychiatry. 2010 Mar;32(1):94-5. doi: 10.1590/s1516-44462010000100019.

Tacrine derivatives and Alzheimer's disease

Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C.

Curr Med Chem. 2010;17(17):1825-38. doi: 10.2174/092986710791111206.

[The role of cyclooxygenases in neurotoxicity of amyloid beta peptides in Alzheimer's disease]

Cakała M, Strosznajder JB.

Neurol Neurochir Pol. 2010 Jan-Feb;44(1):65-79. doi: 10.1016/s0028-3843(14)60407-2.

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study

Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, Grand A, Monstastruc JL, Vellas B.

CNS Drugs. 2010 May;24(5):431-42. doi: 10.2165/11318010-000000000-00000.

Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease

Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniëls H, Dziadulewicz E, Förstl H, Frölich L, Gabryelewicz T, Levin O, Lindesay J, Martínez-Lage P, Monsch A, Tsolaki M, van Laar T.

CNS Neurosci Ther. 2010 Aug;16(4):246-53. doi: 10.1111/j.1755-5949.2010.00141.x. Epub 2010 Apr 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias